keyword
MENU ▼
Read by QxMD icon Read
search

chronic kidney disease mineral and bone disorder

keyword
https://www.readbyqxmd.com/read/29335796/association-between-frailty-and-bone-loss-in-patients-undergoing-maintenance-hemodialysis
#1
Kei Yoneki, Jun Kitagawa, Keika Hoshi, Manae Harada, Takaaki Watanabe, Takahiro Shimoda, Ryota Matsuzawa, Atsushi Yoshida, Yusuke Matsunaga, Yasuo Takeuchi, Kentaro Kamiya, Atsuhiko Matsunaga
Frailty is significantly associated with bone loss in the general population. However, it is unclear whether this association also exists in patients undergoing hemodialysis who have chronic kidney disease-mineral and bone disorder (CKD-MBD). This study aimed to assess the association between frailty and bone loss in patients undergoing hemodialysis. This cross-sectional study included 214 (90 women, 124 men) Japanese outpatients undergoing maintenance hemodialysis three times per week, with a mean age of 67...
January 15, 2018: Journal of Bone and Mineral Metabolism
https://www.readbyqxmd.com/read/29331397/persistent-hyperparathyroidism-as-a-risk-factor-for-long-term-graft-failure-the-need-to-discuss-indication-for-parathyroidectomy
#2
Maria Júlia Correia Lima Nepomuceno Araujo, Janaina Almeida Mota Ramalho, Rosilene Motta Elias, Vanda Jorgetti, William Nahas, Melani Custodio, Rosa M A Moysés, Elias David-Neto
BACKGROUND: Although a successful kidney transplant (KTx) improves most of the mineral and bone disorders (MBD) produced by chronic kidney disease (CKD), hyperparathyroidism may persist (pHPT). Current guidelines recommend parathyroidectomy if serum parathormone is persistently elevated 1 year after KTx, because pHPT has been recently associated with poor graft outcomes. However, whether patients with pHPT and adequate renal function are at risk for long-term graft failure is unknown...
January 10, 2018: Surgery
https://www.readbyqxmd.com/read/29243442/-regression-analysis-of-serum-bone-metabolic-markers-and-traditional-chinese-medicine-syndromes-in-patients-with-ckd-mbd
#3
Hai-Ming Yang, Xian-Jie Meng, Wei Wu, Ying-Lu Liu, Xiao-Juan Zhai
To analyze the interdependent relationship between serum bone metabolic markers and traditional Chinese medicine (TCM) syndromes in patients with chronic kidney disease (stages 3 and 4)-related mineral and bone disorder (CKD-MBD), in order to provide the objective basis for exploring the rules of TCM syndrome differentiation in patients with CKD-MBD. The retrospective survey was conducted to collect 105 cases with CKD (stages 3 and 4)-MBD. General clinical indexes, frequency of TCM syndromes and distribution of TCM syndrome type were investigated...
October 2017: Zhongguo Zhong Yao za Zhi, Zhongguo Zhongyao Zazhi, China Journal of Chinese Materia Medica
https://www.readbyqxmd.com/read/29241204/achieve-your-goals-together-the-easy-and-reasonable-way-to-treat-chronic-kidney-disease-mineral-bone-disorder
#4
Mario Cozzolino
No abstract text is available yet for this article.
December 7, 2017: Blood Purification
https://www.readbyqxmd.com/read/29238762/etelcalcetide-injectable-calcimimetic-for-the-treatment-of-secondary-hyperparathyroidism-in-hemodialysis-dependent-patients
#5
P A Ureña Torres, J Bover, M Cohen-Solal
Chronic kidney disease is associated with mineral and bone disorders that are now considered as a syndrome. One of the major complications of this syndrome is secondary hyperparathyroidism (SHPT). SHPT increases bone turnover and the risk of fracture. SHPT is also associated with cardiovascular calcification and high mortality risk. The classical medical therapies of SHPT lack long-term efficacy and have undesirable effects on serum calcium and phosphate levels. Surgical parathyroidectomy is a radical therapeutic solution potentially exposing patients to a permanent state of hypoparathyroidism among other complications...
September 2017: Drugs of Today
https://www.readbyqxmd.com/read/29237104/osteoporosis-in-patients-with-ckd-a-diagnostic-dilemma
#6
Ann Hallock
Osteoporosis in patients with chronic kidney disease (CKD) is a complex problem, with diagnostic criteria and treatment plans often debated. The debate creates a practice dilemma for clinicians faced with an aging population and an increasing incidence of fragility fractures. This article discusses the dilemma as seen from the perspective of the nephrology clinician on differentiating osteoporosis from other bone mineral disorders in patients with progressive CKD in order to provide the most efficacious and safe care...
January 2017: Nephrology Nursing Journal: Journal of the American Nephrology Nurses' Association
https://www.readbyqxmd.com/read/29233444/assessing-a-traditional-case-based-application-exercise-and-a-student-question-creation-exercise-on-student-performance-and-perceptions
#7
Amulya Tatachar, Carol Kominski
BACKGROUND AND PURPOSE: To compare the impact of a traditional case-based application exercise with a student question creation exercise on a) student exam performance, b) student perceptions of enjoyment, competence, understanding, effort, interest in continuing participation, and interest in the subject. EDUCATIONAL ACTIVITY AND SETTING: Subjects were 84 second-year pharmacy students in a pharmacotherapy course. The research focus was active learning involving the topic of chronic kidney disease-mineral bone disorder...
July 2017: Currents in Pharmacy Teaching & Learning
https://www.readbyqxmd.com/read/29229170/care-of-the-pediatric-patient-on-chronic-dialysis
#8
REVIEW
Annabelle N Chua, Bradley A Warady
Optimal care of the pediatric end-stage renal disease (ESRD) patient on chronic dialysis is complex and requires multidisciplinary care as well as patient/caregiver involvement. The dialysis team, along with the family and patient, should all play a role in choosing the dialysis modality which best meets the patient's needs, taking into account special considerations and management issues that may be particularly pertinent to children who receive peritoneal dialysis or hemodialysis. Meticulous attention to dialysis adequacy in terms of solute and fluid removal, as well as to a variety of clinical manifestations of ESRD, including anemia, growth and nutrition, chronic kidney disease-mineral bone disorder, cardiovascular health, and neurocognitive development, is essential...
November 2017: Advances in Chronic Kidney Disease
https://www.readbyqxmd.com/read/29207226/-the-treatment-of-the-patient-presenting-with-chronic-kidney-disease-ckd-and-fragility-fractures
#9
REVIEW
Andrea Giusti, Maria Fusaro
Fragility fractures occur in all stages of chronic kidney disease (CKD) due to low bone mineral density and poor bone quality (namely osteoporosis), as well as in CKD-mineral and bone disorders (CKD-MBD). As in postmenopausal women and older adults, the prompt identification of CKD subjects with a history of fragility fractures is crucial in order to implement strategies to reduce the risk of new fragility fractures and their consequences. The treatment of severe osteoporosis for patients with stages 1-3 CKD should not differ from patients without CKD, while clinical decisions and pharmacological treatments in subjects with stages 4-5/5D CKD differ greatly, being more tricky and challenging...
December 5, 2017: Giornale Italiano di Nefrologia: Organo Ufficiale Della Società Italiana di Nefrologia
https://www.readbyqxmd.com/read/29195858/phosphate-binder-use-in-us-dialysis-patients-prevalence-costs-evidence-and-policies
#10
Wendy L St Peter, Lori D Wazny, Eric D Weinhandl
Medicare costs for phosphate binders for US dialysis patients and patients with chronic kidney disease enrolled in Medicare Part D exceeded $1.5 billion in 2015. Previous data have shown that Part D costs for mineral and bone disorder medications increased faster than costs for all Part D medications for dialysis patients. Despite extensive use of phosphate binders and escalating costs, conclusive evidence is lacking that they improve important clinical end points in dialysis patients or non-dialysis-dependent patients with chronic kidney disease...
November 28, 2017: American Journal of Kidney Diseases: the Official Journal of the National Kidney Foundation
https://www.readbyqxmd.com/read/29187373/klotho-activin-a-in-kidney-injury-plasma-klotho-is-maintained-in-unilateral-obstruction-despite-no-upregulation-of-klotho-biosynthesis-in-contralateral-kidney
#11
Anders Nordholm, Maria L Mace, Eva Gravesen, Jacob Hofman-Bang, Marya Morevati, Klaus Olgaard, Ewa Lewin
In a new paradigm of etiology related to Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) kidney injury may cause induction of factors in the injured kidney that are released into the circulation and thereby initiate and maintain renal fibrosis and CKD-MBD. Klotho is believed to ameliorate renal fibrosis and CKD-MBD, while ActivinA might have detrimental effects. The unilateral ureter obstruction (UUO) model is used here to examine this concept by investigating early changes related to renal fibrosis in obstructed kidney, untouched contralateral kidney and vasculature, which might be affected by secreted factors from the obstructed kidney, and compared to unilateral nephrectomized controls (UNX)...
November 29, 2017: American Journal of Physiology. Renal Physiology
https://www.readbyqxmd.com/read/29181658/effect-of-ferric-citrate-hydrate-on-fgf23-and-pth-levels-in-patients-with-non-dialysis-dependent-chronic-kidney-disease-with-normophosphatemia-and-iron-deficiency
#12
Akira Iguchi, Suguru Yamamoto, Mihoko Yamazaki, Kazuyuki Tasaki, Yasushi Suzuki, Junichiro James Kazama, Ichiei Narita
BACKGROUND: In patients with normophosphatemia with chronic kidney disease (CKD), fibroblast growth factor 23 (FGF23) and parathyroid hormone (PTH) increase urinary phosphate excretion while maintaining serum phosphate within the normal range. Recent reports have shown that, in this stage, phosphate binders do not decrease serum FGF23 and PTH levels. Iron deficiency promotes transcription of FGF23 and iron-supplementation for iron deficiency decreases serum FGF23 levels. We hypothesized that ferric citrate hydrate, an iron-based phosphate binder, will decrease serum FGF23 levels in patients with non-dialysis-dependent CKD with normophosphatemia and iron deficiency...
November 27, 2017: Clinical and Experimental Nephrology
https://www.readbyqxmd.com/read/29175269/sclerostin-deficiency-modifies-the-development-of-ckd-mbd-in-mice
#13
Nadine Kaesler, Anja Verhulst, Annelies De Maré, Annika Deck, Geert J Behets, Ayshe Hyusein, Pieter Evenepoel, Jürgen Floege, Nikolaus Marx, Anne Babler, Ina Kramer, Michaela Kneissel, Rafael Kramann, Daniel Weis, Patrick C D'Haese, Vincent M Brandenburg
Sclerostin is a soluble antagonist of canonical Wnt signaling and a strong inhibitor of bone formation. We present experimental data on the role of sclerostin in chronic kidney disease - bone mineral disorder (CKD-MBD). METHODS: We performed 5/6 nephrectomies in 36-week-old sclerostin-deficient (SOST-/-) B6-mice and in C57BL/6J wildtype (WT) mice. Animals received a high phosphate diet for 11weeks. The bones were analyzed by high-resolution micro-computed tomography (μCT) and quantitative bone histomorphometry...
November 21, 2017: Bone
https://www.readbyqxmd.com/read/29163188/elevated-levels-of-peripheral-kynurenine-decrease-bone-strength-in-rats-with-chronic-kidney-disease
#14
Bartlomiej Kalaska, Krystyna Pawlak, Tomasz Domaniewski, Ewa Oksztulska-Kolanek, Beata Znorko, Alicja Roszczenko, Joanna Rogalska, Malgorzata M Brzoska, Pawel Lipowicz, Michal Doroszko, Anna Pryczynicz, Dariusz Pawlak
The diagnosis and treatment of bone disorders in patients with chronic kidney disease (CKD) represent a clinical challenge. CKD leads to mineral and bone complications starting early in the course of renal failure. Recently, we have observed the positive relationship between intensified central kynurenine turnover and bone strength in rats with subtotal 5/6 nephrectomy (5/6 Nx)-induced CKD. The aim of the present study was to determine the association between peripheral kynurenine pathway metabolites and bone strength in rats with 5/6 Nx-induced CKD...
2017: Frontiers in Physiology
https://www.readbyqxmd.com/read/29161692/association-between-extreme-values-of-markers-of-chronic-kidney-disease-mineral-and-bone-disorder-and-5-year-mortality-among-prevalent-hemodialysis-patients
#15
Jin-Gang Zhu, Jin-Bor Chen, Ben-Chung Cheng, Chih-Hsiung Lee, Gang Long, Yu-Shu Chien
BACKGROUND/AIMS: We examined the association between markers of chronic kidney disease - mineral and bone disorder (CKD-MBD) and mortality in hemodialysis (HD) patients. METHODS: We retrospectively reviewed the association between markers of CKD-MBD and mortality in 1,126 HD patients from 2009 to 2013 with baseline (B), time-average (TA), and time-dependent (TD) Cox regression models. RESULTS: Hypercalcemia (10.9-11.9 mg/dL) indicated an increased risk of all-cause mortality (TA: hazard ratio [HR] 3...
November 22, 2017: Blood Purification
https://www.readbyqxmd.com/read/29153145/ketteler-m-block-ga-evenepoel-p-et%C3%A2-al-executive-summary-of-the-2017-kdigo-chronic-kidney-disease-mineral-and-bone-disorder-ckd-mbd-guideline-update-what-s-changed-and-why-it-matters-kidney%C3%A2-int-2017-92-26-36
#16
https://www.readbyqxmd.com/read/29144803/endocrine-manifestations-of-primary-hyperoxaluria
#17
Shatha Murad, Yuval Eisenberg
OBJECTIVE: Primary hyperoxaluria type 1 (PH1) is a rare metabolic disorder of oxalate overproduction. It is associated with urolithiasis and nephrocalcinosis which progress to ESRD and systemic oxalosis. As oxalate deposits in tissues, non-parathyroid hormone (nonPTH) mediated hypercalcemia, oxalate osteopathy, primary hypothyroidism and primary hypogonadism develop. In this review, we will present a case of PH1 and provide an overview of this clinical entity and its endocrine manifestations...
November 16, 2017: Endocrine Practice
https://www.readbyqxmd.com/read/29107998/impact-of-surgical-parathyroidectomy-on-chronic-kidney-disease-mineral-and-bone-disorder-ckd-mbd-a-systematic-review-and-meta-analysis
#18
REVIEW
Mugurel Apetrii, David Goldsmith, Ionut Nistor, Dimitrie Siriopol, Luminita Voroneanu, Dragos Scripcariu, Marc Vervloet, Adrian Covic
For more than 6 decades, many patients with advanced chronic kidney disease (CKD) have undergone surgical parathyroidectomy (sPTX) for severe secondary hyperparathyroidism (SHPT) mainly based historical clinical practice patterns, but not on evidence of outcome.We aimed in this meta-analysis to evaluate the benefits and harms of sPTX in patients with SHPT. We searched MEDLINE (inception to October 2016), EMBASE and Cochrane Library (through Issue 10 of 12, October 2016) and website clinicaltrials.gov (October 2016) without language restriction...
2017: PloS One
https://www.readbyqxmd.com/read/29104033/oral-and-maxillofacial-manifestations-of-chronic-kidney-disease-mineral-and-bone-disorder-a-multicenter-retrospective-study
#19
Flávia Sirotheau Corrêa Pontes, Márcio Ajudarte Lopes, Lucas Lacerda de Souza, Diogo Dos Santos da Mata Rezende, Alan Roger Santos-Silva, Jacks Jorge, Wagner Gomes da Silva, Fábio Ramôa Pires, André Caroli Rocha, Wladimir Gushiken de Campos, Milena Coelho Fernandes Caldato, Regina Matsunaga Martin, Felipe Paiva Fonseca, Hélder Antônio Rebelo Pontes
OBJECTIVE: To describe the oral and maxillofacial manifestations of patients diagnosed with chronic kidney disease-mineral and bone disorders. STUDY DESIGN: Over a 13-year period, clinicopathologic data of patients diagnosed with CKD-MBD who had oral and maxillofacial alterations were retrieved from the files of 4 Brazilian institutions. Data included clinical, radiographic, microscopic, and biochemical findings; treatment employed; and follow-up status. RESULTS: Twenty-one cases were identified, with 13 patients diagnosed as brown tumor of hyperparathyroidism (BTH) and 8 as osteitis fibrosa/renal osteodystrophy (OF/RO) (4 of them clinically consistent with Sagliker syndrome)...
January 2018: Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology
https://www.readbyqxmd.com/read/29080646/the-use-of-vitamin-d-metabolites-and-analogues-in-the-treatment-of-chronic-kidney-disease
#20
REVIEW
Ladan Zand, Rajiv Kumar
Chronic kidney disease (CKD) and end-stage renal disease (ESRD) are associated with abnormalities in bone and mineral metabolism, known as CKD-bone mineral disorder. CKD and ESRD cause skeletal abnormalities characterized by hyperparathyroidism, mixed uremic osteodystrophy, osteomalacia, adynamic bone disease, and frequently enhanced vascular and ectopic calcification. Hyperparathyroidism and mixed uremic osteodystrophy are the most common manifestations due to phosphate retention, reduced concentrations of 1,25-dihydroxyvitamin D, intestinal calcium absorption, and negative calcium balance...
December 2017: Endocrinology and Metabolism Clinics of North America
keyword
keyword
53758
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"